Introduction 44 45
Francisella tularensis is a Gram-negative intracellular pathogen that is 46 the causative agent of tularemia. The disease is prevalent in many countries 47 in the northern hemisphere, including the United States (9) where the reported 48 number of cases averages between 100-200 annually (12). The pathogen is 49 infectious by a number of routes, has a low infectious dose and is readily 50 transmitted by the airborne route and so is included on the CDC list of select 51 agents that have potential to pose a major threat to public health and safety 52
(3). 53
Currently, the recommended preferred treatment for adults with tularemia is 54 systemic gentamicin or streptomycin, or alternatively doxycycline or 55 (1, 22) . Levofloxacin has already proven utility in the biodefense arena as it 69 been approved for treatment of inhalational anthrax in both adults and 70 children (7, 21), thus reducing the number of antibiotics required in the 71
arsenal. 72
In order to determine the efficacy of pre or post-exposure therapies, 73 there is a need to develop and characterise animal models of inhalational 74 tularemia. To date, most research on tularemia has focussed on developing 75 murine models of infection (5). This has increased the understanding of 76 disease progression and has identified important immunological responses to 77 infection. However, in order to undertake the pivotal studies that would be 78 required for licensure of any therapy, non-human primate (NHP) models of 79 infection are required. Previous work has demonstrated that the common 80 marmoset (Callithrix jacchus) is susceptible to experimental inhalational 81 tularemia and develops a lethal infection representative of human disease 82 (23). 83
The purpose of this work was to investigate the use of orally 84 administered levofloxacin as a post-exposure therapy for tularemia using the 85 common marmoset. Initially, this involved establishing the pharmacokinetic 86 parameters in the marmoset and, using this data, testing the efficacy of 87 levofloxacin against inhalational tularemia. 88
. 89
on April 2, 2020 by guest http://aac.asm.org/ Downloaded from Animals. Healthy, sexually mature common marmosets (Callithrix 92 jacchus) were obtained from the Dstl Porton Down breeding colony and 93 housed in female and vasectomised male pairs. Animals were aged between 94 25 to 64 months and weighed between 310 and 560 g at the time of study. 95
The animals were allowed free access to food and water as well as 96 environmental enrichment. Prior to use in challenge studies, all animals were 97 surgically implanted intra-peritoneally (i.p.), under general anaesthesia 98 (ketamine/metetomidine/isofluorane), with a Remo 200 device to record core 99 body temperature (Tc) remotely (Remo Technologies Ltd, Salisbury, UK). 100
Data were transmitted from the Remo 200 devices at thirty second intervals to 101 locally placed antennas and relayed to receivers. Data were analysed using 102 6 heparin anticoagulant and thoroughly mixed, prior to centrifugation for 5 115 minutes at 13,000 rpm. Plasma was collected into a labelled, sterile eppendorf 116 tube and stored at -70°C until analysis. The PK of levofloxacin was investigated in two studies (single-and multi-267 dose) and the data were compared to PK parameters of rhesus monkeys and 268 humans (2, 4, 14, 17). These are shown in Table 3 . 269
The human dose of levofloxacin is 500 mg per day, achieving a serum C max of 270 6.2 µg/mL and AUC of 48.3 µg/mL/h. Therefore, in order to match the 271 marmoset dosage to the human dosage in the efficacy study, it was 272 determined that the marmoset dose should be reduced from 40 to 16.5 mg/kg, 273 based on the C max . Assuming a linear relationship, this gives marmoset 274 plasma C max of 6.2 µg/mL. This also lowers the predicted AUC (24 µg/mL/h) to 275 below the human target AUC, but dosing at shorter intervals would have been 276 necessary to more accurately match this parameter. 277
Interestingly, the T ½ in rhesus monkeys (2 h) and marmosets (2.4 h) is lower 278
than the human value of approximately 7 h, indicating more rapid clearance 279 (Table 1 ). However, the C max and AUC for marmosets are higher than the 280 human values, which in turn are higher than for rhesus monkeys. This may, at 281 on April 2, 2020 by guest http://aac.asm.org/
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In the current study, the time to death, activity, temperature profile and 284 bacterial load at post mortem in the non-treated animals was consistent with 285 previously reported data (23). Clinical parameters were investigated in the 286 current study and showed a statistically significant decrease in the platelets 287 and increase in the alkaline phosphatase levels, as well as notable changes in 288 the levels of potassium, ALT and glucose from the baseline. This is consistent 289 with human tularemia (16, 10). Following a ten day dosing regimen, there was 290 100% survival in the levofloxacin treated group, with no evidence of overt 291 clinical signs. The temperature and activity of these animals remained 292 comparable to the baseline data and at post-mortem, 14 days after the 293 cessation of antibiotic dosing; no bacteria were recovered from any of the 294 organs of assessed animals. However, slight changes in the clinical 295 parameters were noted including some mild liver dysfunction and a drop in the 296 platelet levels. 297
These results indicate that orally-administered levofloxacin is highly effective 298 in preventing the onset of acute inhalational tularemia. They also suggest that 299 bacterial clearance has been achieved and that relapse of infection, following 300 treatment, may be unlikely. Murine studies indicate that intra-peritoneal 301 administration of levofloxacin is 100% effective against intra-nasal challenge, 302 even when administration is delayed up to 72 hours post-challenge (19) . 303
Moreover, it has previously been reported that intravenous administration of 304 500mg of levofloxacin has been successful in treating human tularemia 305 without relapse (1, 22) . As the oral and intravenous bioavailability of 306 on April 2, 2020 by guest http://aac.asm.org/
In conclusion, orally administered levofloxacin was efficacious as post-309 exposure prophylaxis against acute inhalational tularemia in the common 310 marmoset. In addition, the marmoset appears to be an appropriate animal DeBord for their support. 318
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